About Outpace Bio
Outpace Bio is pioneering the future of cell therapy for solid tumors by harnessing unrivaled AI-powered protein design. Our mission is to program immune cells for enhanced function inside patients, overcoming key barriers such as poor tumor access, weak survival, antigen escape, and dose-related toxicity. By creating and integrating modular, plug-and-play technology assets, we are developing cell therapies with unprecedented efficacy, transforming how engineered T cells interact with cancer and the immune system to deliver life-changing outcomes. Our multidisciplinary team of scientists, engineers, coders, and cell therapy developers works at the cutting edge of computational protein design, synthetic biology, and immunology. Together, we are reimagining how cells function to unlock novel therapeutic possibilities.Located in Seattle’s vibrant biotech hub overlooking scenic South Lake Union, Outpace Bio is led by pioneers in computational protein design and engineered cell therapies. Our culture is built on a foundation of respect and inclusion, which are fundamental to how we collaborate to revolutionize cell therapy through groundbreaking innovation rooted in rigorous science.
Our Commitment to Diversity
At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences. We are committed to cultivating an open, diverse, and inclusive culture for all employees. Recognizing that the best candidates do not always match all criteria of the job description, we encourage you to apply if you think you would be a good fit for the role and are inspired by our mission to cure disease by pushing the boundaries of biology.
Our Momentum
In August 2024, Outpace Bio secured an oversubscribed $144 million Series B financing, led by RA Capital Management and supported by a premier syndicate of life science investors. This funding accelerates our pipeline of programmed T cell therapies, including our lead candidate OPB-101, a mesothelin-specific chimeric antigen receptor (CAR) T cell enhanced by Outpace’s proprietary OUTSMART™, OUTLAST™, OUTSPACER™, and OUTSAFE™ technologies. OPB-101 is advancing toward IND clearance and first dosing in 2025 for patients with advanced platinum-resistant ovarian cancers. The Series B investment also supports the expansion of our pipeline, enabling us to develop additional transformative therapies leveraging our innovative plug-and-play technology platform.
Outpace Bio is seeking a highly talented and experienced Associate Director/Director of Translational Sciences to lead the development and execution of translational strategy for assigned cellular therapies in solid tumor programs. The successful candidate will design and implement fit-for-purpose translational/biomarker strategies for clinical programs, focusing on delivering informative and actionable translational data to support clinical development, including patient selection and stratification, pharmacokinetic, pharmacodynamic, mechanism of action, resistance and toxicity, prognostic and predictive biomarkers. This critical role will manage mostly outsourced assay development/validation, support operationalization of the trial with Central and Specialty Labs, and deliver data and interpretation to the asset team and other stakeholders and contribute to asset team strategy and regulatory submissions. The ideal candidate will have expertise in translational strategy design and execution for cell therapies in oncology, with a proven track record of initiating and delivering on translational plans in phase 1 and later stages clinical trials, and experience with patient selection and CDx strategy. This individual will work in a fast-paced, highly dynamic and collaborative environment, in close collaboration with diverse cross-functional teams. The position reports to the Head of Translational Sciences, and may be located in Seattle, WA or remote.
